Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Calcified Tissue International
Erschienen in: Calcified Tissue International 4/2021

15.11.2020 | Review

Chronic Kidney Disease—Mineral and Bone Disorders: Pathogenesis and Management

verfasst von: Jorge B. Cannata-Andía, Beatriz Martín-Carro, Julia Martín-Vírgala, Javier Rodríguez-Carrio, José Joaquín Bande-Fernández, Cristina Alonso-Montes, Natalia Carrillo-López

Erschienen in: Calcified Tissue International | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

The key players of the chronic kidney disease-mineral and bone disorders (CKD-MBD) are calcium, phosphate, PTH, FGF23, and the vitamin D hormonal system. The progressive reduction of kidney function greatly modifies the tightly interrelated mechanisms that control these parameters. As a result, important changes occur in the bone and mineral hormonal axis, leading to changes in bone turnover with relevant consequences in clinical outcomes, such as decrease in bone mass with increased bone fragility and bone fractures and increased vascular and valvular calcification, also with great impact in the cardiovascular outcomes. So far, the knowledge of the mineral and bone disorders in CKD and the increased variety of efficacious therapies should lead to a better prevention and management of CKD-MBD.
Literatur
1.
Cannata-Andia J, Rodriguez-Garcia M (2015) Metabolismo Calcio-Fósforo y sus alteraciones. In: Avendaño H (ed) Nefrología Clínica, L. Editorial médicaPanamericana, Madrid, pp 147–160
2.
Jüppner H, Kronenberg HM (2003) Parathyroid hormone. In: Favus MJ (ed) Primer on metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 117–124
3.
Goodman WG et al (2003) Renal osteodystrophy in adults and children. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. American Society for Bone and Mineral Research, Washington, pp 430–447
4.
Favus MJ, Goltzman D (2013) Regulation of calcium and magnesium. In: Rosen CJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism. Wiley-Blackwell, Hoboken, pp 171–179
5.
Vorland CJ et al (2017) Effects of excessive dietary phosphorus intake on bone health. Curr Osteoporos Rep 15(5):473–482PubMedPubMedCentral
6.
Cannata Andia J et al (2014) Mineral and bone disorders in chronic kidney disease. In: Arici M (ed) Management of chronic kidney disease. Springer, Berlin, pp 223–239
7.
Moe S et al (2006) Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953PubMed
8.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group (2009) KDIGO clinical practice guideline for the diagnosis evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 113:S1-130
9.
Spasovski GB (2004) Bone biopsy as a diagnostic tool in the assessment of renal osteodystrophy. Int J Artif Organs 27(11):918–923PubMed
10.
Olgaard K, Salusky I, Silver J (2010) The spectrum of mineral and bone disorders in chronic kidney disease. Oxford University Press, Oxford
11.
Evenepoel P, Bover J, Ureña Torres P (2016) Parathyroid hormone metabolism and signaling in health and chronic kidney disease. Kidney Int 90(6):1184–1190PubMed
12.
Silver J (2000) Molecular mechanisms of secondary hyperparathyroidism. Nephrol Dial Transpl 15(Suppl 5):2–7
13.
Centeno PP et al (2019) Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat Commun 10(1):4693PubMedPubMedCentral
14.
Tominaga Y et al (1997) Histopathology, pathophysiology, and indications for surgical treatment of renal hyperparathyroidism. Semin Surg Oncol 13(2):78–86PubMed
15.
Lorenzo V et al (1986) Prevalencia de las distintas formas histológicas de osteodistrofia renal, con especial referencia a la osteomalacia. Nefrología 6(2):25–33
16.
Moriniere P et al (1989) Disappearance of aluminic bone disease in a long term asymptomatic dialysis population restricting A1(OH)3 intake: emergence of an idiopathic adynamic bone disease not related to aluminum. Nephron 53(2):93–101PubMed
17.
Sherrard DJ et al (1993) The spectrum of bone disease in end-stage renal failure–an evolving disorder. Kidney Int 43(2):436–442PubMed
18.
Hercz G et al (1993) Aplastic osteodystrophy without aluminum: the role of “suppressed” parathyroid function. Kidney Int 44(4):860–866PubMed
19.
Torres A et al (1995) Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47(5):1434–1442PubMed
20.
Ferreira A et al (2008) Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J Am Soc Nephrol 19(2):405–412PubMedPubMedCentral
21.
Levin A et al (2007) Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 71(1):31–38PubMed
22.
Ketteler M et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 92(1):26–36PubMed
23.
Kidney Disease Outcome Quality Initiative (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39(2 Suppl 1):S1-266
24.
Fernandez-Martin JL et al (2015) Improvement of mineral and bone metabolism markers is associated with better survival in haemodialysis patients: the COSMOS study. Nephrol Dial Transpl 30(9):1542–1551
25.
Fernandez-Martin JL et al (2019) Serum phosphate optimal timing and range associated with patients survival in haemodialysis: the COSMOS study. Nephrol Dial Transpl 34(4):673–681
26.
Tentori F et al (2008) Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Am J Kidney Dis 52(3):519–530PubMed
27.
Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017) Clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 7(1):1–59
28.
Bover J et al (2021) The non-invasive diagnosis of bone disorders in CKD. Calcif Tissue Int. (in press)
29.
Pimentel A et al (2021) Bone fragility fractures in CKD patients. Calcif Tissue Int. (in press)
30.
Bucur RC et al (2015) Low bone mineral density and fractures in stages 3–5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 26(2):449–458PubMed
31.
Silva BC, Bilezikian JP (2015) Parathyroid hormone: anabolic and catabolic actions on the skeleton. Curr Opin Pharmacol 22:41–50PubMedPubMedCentral
32.
Sprague SM et al (2016) Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis. Am J Kidney Dis 67(4):559–566PubMed
33.
34.
Cannata-Andia JB et al (2013) Use of phosphate-binding agents is associated with a lower risk of mortality. Kidney Int 84:998–1008PubMed
35.
Mendez-Chacon P et al (2018) Influencia de la sobrecarga de calcio sobre el metabolismo óseo y mineral en 55 centros de hemodiálisis de Lima. Nefrologia 38(3):279–285PubMed
36.
Alvarez-Hernandez D et al (2005) Long-term response of cultured rat parathyroid glands to calcium and calcitriol: the effect of cryopreservation. J Nephrol 18(2):141–147PubMed
37.
Torregrosa JV et al (2011) Spanish Society of Nephrology recommendations for controlling mineral and bone disorder in chronic kidney disease patients (S.E.N.–M.B.D.). Nefrologia 31(Suppl 1):3–32PubMed
38.
Floege J et al (2011) Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transpl 26(6):1948–1955
39.
Naves-Diaz M et al (2011) Calcium, phosphorus, PTH and death rates in a large sample of dialysis patients from Latin America. The CORES Study. Nephrol Dial Transpl 26(6):1938–1947
40.
Carrillo-Lopez N et al (2008) Simultaneous changes in the calcium-sensing receptor and the vitamin D receptor under the influence of calcium and calcitriol. Nephrol Dial Transpl 23(11):3479–3484
41.
Fernandez-Martin JL et al (2013) COSMOS: the dialysis scenario of CKD-MBD in Europe. Nephrol Dial Transpl 28(7):1922–1935
42.
Rodriguez Garcia M, Naves Diaz M, Cannata Andia JB (2005) Bone metabolism, vascular calcifications and mortality: associations beyond mere coincidence. J Nephrol 18(4):458–463PubMed
43.
Roman-Garcia P et al (2011) Vascular calcification in patients with chronic kidney disease: types, clinical impact and pathogenesis. Med Princ Pract 20(3):203–212PubMed
44.
Lomashvili K, Garg P, O’Neill WC (2006) Chemical and hormonal determinants of vascular calcification in vitro. Kidney Int 69(8):1464–1470PubMed
45.
O’Neill WC, Lomashvili KA (2010) Recent progress in the treatment of vascular calcification. Kidney Int 78(12):1232–1239PubMedPubMedCentral
46.
Montezano AC et al (2010) Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 56(3):453–462PubMed
47.
Mune S et al (2009) Mechanism of phosphate-induced calcification in rat aortic tissue culture: possible involvement of Pit-1 and apoptosis. Clin Exp Nephrol 13(6):571–577PubMed
48.
49.
O’Neill WC et al (2011) Treatment with pyrophosphate inhibits uremic vascular calcification. Kidney Int 79(5):512–517PubMed
50.
Villa-Bellosta R (2020) New insights into endogenous mechanisms of protection against arterial calcification. Atherosclerosis 306:68–74PubMed
51.
Cannata-Andia JB, Roman-Garcia P, Hruska K (2011) The connections between vascular calcification and bone health. Nephrol Dial Transpl 26(11):3429–3436
52.
Rodriguez-Garcia M et al (2009) Vascular calcifications, vertebral fractures and mortality in haemodialysis patients. Nephrol Dial Transpl 24(1):239–246
53.
Asci G et al (2011) The link between bone and coronary calcifications in CKD-5 patients on haemodialysis. Nephrol Dial Transpl 26(3):1010–1015
54.
Carrillo-Lopez N et al (2016) Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease. Kidney Int 90(1):77–89PubMed
55.
Carrillo-Lopez N et al (2021) Role of the RANK/RANKL/OPG and Wnt/ß-catenin systems in CKD Bone and cardiovascular disorders. Calcif Tissue Int. (in press)
56.
Luo J et al (2016) LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med 22(5):539–546PubMed
57.
London GM et al (2003a) Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int Suppl 84:S88-93
58.
London GM et al (2003b) Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transpl 18(9):1731–1740
59.
Raggi P (2018) Atherosclerosis imaging to refine cardiovascular risk assessment in diabetic patients: computed tomography and positron emission tomography applications. Atherosclerosis 271:77–83PubMed
60.
Raggi P, Achenbach S (2010) Computed tomography for atherosclerosis and coronary artery disease imaging. Discov Med 9(45):98–104PubMed
61.
Bellasi A, Raggi P (2005) Diagnostic and prognostic value of coronary artery calcium screening. Curr Opin Cardiol 20(5):375–380PubMed
62.
Kauppila LI et al (1997) New indices to classify location, severity and progression of calcific lesions in the abdominal aorta: a 25-year follow-up study. Atherosclerosis 132(2):245–250PubMed
63.
Adragao T et al (2004) A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transpl 19:1480–1488
64.
Ketteler M, Floege J (2010) Clinical management of vascular and soft tissue calcifications in chronic kidney disease patients. In: Olgaard K, Salusky I, Silver J (eds) The spectrum of mineral and bone disorders in chronic kidney disease. Oxford University Press, Oxford, pp 317–331
65.
Perelló J et al (2020) Mechanism of action of SNF472, a novel calcification inhibitor to treat vascular calcification and calciphylaxis. Br J Pharmacol 177(19):4400–4415PubMed
66.
Raggi P et al (2020) Slowing progression of cardiovascular calcification with SNF472 in patients on hemodialysis: results of a randomized phase 2b study. Circulation 141(9):728–739PubMed
67.
Fusaro M et al (2021) Vitamin K in CKD bone disordes. Calcif Tissue Int. (in press)
68.
Nigwekar SU, Thadhani R, Brandenburg VM (2018) Calciphylaxis. N Engl J Med 378(18):1704–1714PubMed
69.
Torregrosa JV et al (2012) Successful treatment of calcific uraemic arteriolopathy with bisphosphonates. Nefrologia 32(3):329–334PubMed
70.
Torregrosa JV, Cucchiari D (2018) 50 key questions on Calciphylaxis. In: Permanyer P (ed) Chronic kidney disease, Barcelona
71.
Ong S, Coulson IH (2012) Diagnosis and treatment of calciphylaxis. Skinmed 10(3):166–170PubMed
72.
Singh RP, Derendorf H, Ross EA (2011) Simulation-based sodium thiosulfate dosing strategies for the treatment of calciphylaxis. Clin J Am Soc Nephrol 6(5):1155–1159PubMedPubMedCentral
73.
Ariyoshi T et al (2006) Effect of etidronic acid on arterial calcification in dialysis patients. Clin Drug Investig 26(4):215–222PubMed
74.
Neven EG, De Broe ME, D’Haese PC (2009) Prevention of vascular calcification with bisphosphonates without affecting bone mineralization: a new challenge? Kidney Int 75(6):580–582PubMed
75.
Persy V, De Broe M, Ketteler M (2006) Bisphosphonates prevent experimental vascular calcification: treat the bone to cure the vessels? Kidney Int 70(9):1537–1538PubMed
76.
Toussaint ND et al (2010) Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 56(1):57–68PubMed
77.
Cannata-Andia JB, Rodriguez Garcia M, Gomez Alonso C (2013) Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol 26(1):73–80PubMed
78.
World Health Organ (1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129
79.
Jamal SA et al (2013) Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 382:1268–1277PubMed
80.
Bover J et al (2018) Osteoporosis, bone mineral density and CKD-MBD complex (I): diagnostic considerations. Nefrologia 38(5):476–490PubMed
81.
Bover J et al (2019) Osteoporosis, bone mineral density and CKD-MBD (II): therapeutic implications. Nefrologia 39(3):227–242PubMed
82.
Kazama JJ, Iwasaki Y, Fukagawa M (2013) Uremic osteoporosis. Kidney Int Suppl 3(5):446–450
83.
84.
Hernández E et al (2003) Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis. Kidney Int 63(6):2269–2274PubMed
85.
Evenepoel P, D’Haese P, Brandenburg V (2015) Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int 88(2):235–240PubMed
86.
Pereira L, Frazão JM (2020) The bone-vessel axis in chronic kidney disease: an update on biochemical players and its future role in laboratory medicine. Clin Chim Acta 508:221–227PubMed
87.
88.
Metadaten
Titel
Chronic Kidney Disease—Mineral and Bone Disorders: Pathogenesis and Management
verfasst von
Jorge B. Cannata-Andía
Beatriz Martín-Carro
Julia Martín-Vírgala
Javier Rodríguez-Carrio
José Joaquín Bande-Fernández
Cristina Alonso-Montes
Natalia Carrillo-López
Publikationsdatum
15.11.2020
Verlag
Springer US
Erschienen in
Calcified Tissue International / Ausgabe 4/2021
Print ISSN: 0171-967X
Elektronische ISSN: 1432-0827
DOI
https://doi.org/10.1007/s00223-020-00777-1

Weitere Artikel der Ausgabe 4/2021

Calcified Tissue International 4/2021 Zur Ausgabe

Review

The Role of Bone Biopsy in the Management of CKD-MBD

Review

Bone Mineral Disease After Kidney Transplantation

Review

The Non-invasive Diagnosis of Bone Disorders in CKD

Review

Vitamin K in CKD Bone Disorders

Editorial

Bone in CKD, a Fascinating Evolving Topic

Review

Traditional and Non-traditional Risk Factors for Osteoporosis in CKD

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Vorhofflimmern bei Jüngeren gefährlicher als gedacht

06.05.2024 Vorhofflimmern Nachrichten

Immer mehr jüngere Menschen leiden unter Vorhofflimmern. Betroffene unter 65 Jahren haben viele Risikofaktoren und ein signifikant erhöhtes Sterberisiko verglichen mit Gleichaltrigen ohne die Erkrankung.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise